Onkologie. 2013:7(5):225-228

Hereditary breast cancer

Martina Zimovjanová

Onkologická klinika VFN a 1. LF UK Praha

Hereditary predisposition causes neoplastic disease in 5–10% of patients with breast cancer. Molecular- genetic testing of high- penetrant

genes is standard of clinical care about patients with breast and ovarian cancer, who meet the criteria for testing. Therapy of hereditary

mutation associated breast cancer is not different from sporadic breast cancer therapy nowadays. Prognosis of patients with BRCA1, BRCA2

mutation associated breast cancer may be different from sporadic breast cancer patients due to the existing systemic treatment options

and higher risk of other malignant disease. The aim of this article is to review the current knowledge of BRCA1 and BRCA2 functions and

other predisposition genes, comparison of hereditary BRCA mutation associated breast cancer with „BRCAness“ sporadic breast cancer,

and distinct effectiveness of oncological treatment in this specific subgroup of breast cancer patients.

Keywords: BRCA1, BRCA2, triple negative breast cancer, chemotherapy, PARP inhibitors

Published: November 1, 2013  Show citation